Lung Cancer

In this disease area you will find articles about this disease, including conference reports, international medical news and journal articles.

Use of prophylactic cranial irradiation for extensive-stage small-cell lung cancer may be dropping (22/8/2019) ›AstraZeneca Imfinzi combination fails advanced lung cancer study (21/8/2019) ›Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC (23/7/2019) ›Early results from TAK-788 in NSCLC with EGFR exon 20 insertions (23/7/2019) ›Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC (23/7/2019) ›Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC (23/7/2019) ›Lurbinectedin shows promise as second-line therapy for SCLC (23/7/2019) ›Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC (23/7/2019) ›Overcoming the challenges of immunotherapy in non–small cell lung cancer (23/7/2019) ›Lung-cancer-screening eligibility should be expanded (18/7/2019) ›WHO keeps key lung cancer drugs off its essential medicines list (9/7/2019) ›Antioxidants enhance lung cancer metastasis by stabilizing BACH1 (8/7/2019) ›High prevalence of PD-L1 expression in non-small-cell lung cancer (5/7/2019) ›Lung-cancer screening may be warranted in bladder-cancer patients (2/7/2019) ›Brain irradiation as treatment option (1/7/2019) ›Other I-O combinations (1/7/2019) ›Predictive diagnostics for I-O (1/7/2019) ›Molecular characteristics of SCLC (1/7/2019) ›Electromagnetic navigation bronchoscopy (1/7/2019) ›Immunotherapy in SCLC: trial data (1/7/2019) ›Post-discontinuation immunotherapy in PACIFIC (1/7/2019) ›Treatment options in early NSCLC (1/7/2019) ›Systemic therapy of brain metastases (1/7/2019) ›Experiences from France (1/7/2019) ›Experiences from Germany (1/7/2019) ›I-O monotherapy (1/7/2019) ›Genomic and immune profiling (1/7/2019) ›Incidence and local treatment (1/7/2019) ›Tumour, node, and metastasis (TNM) staging system (1/7/2019) ›Post-study immunotherapy in MYSTIC (1/7/2019) ›How can societies help to implement personalised treatment? (1/7/2019) ›Combo I-O plus chemotherapy (1/7/2019) ›Lung cancer radiotherapy tied to higher cardiac mortality (18/6/2019) ›Broadening eligibility for lung cancer trials could have huge impact (5/6/2019) ›Pembrolizumab quadruples survival in selected advanced non-small cell lung cancer patients (3/6/2019) ›Atezolizumab added to chemo ups survival in lung cancer (31/5/2019) ›Longer lung-cancer-screening intervals may sometimes be OK (27/5/2019) ›Vein-first ligation in lung-cancer surgery may increase survival (14/5/2019) ›New technique for minimally invasive lung cancer surgery promising (10/5/2019) ›Deep-learning model may help predict NSCLC outcomes, survival (30/4/2019) ›Higher radiation doses tied to increased longevity in node-negative lung cancer (30/4/2019) ›Lung-cancer survival worse in patients with pulmonary fibrosis (25/4/2019) ›Electromagnetic navigation: an instant hit? (11/4/2019) ›Survival benefit persists despite post-discontinuation therapy (11/4/2019) ›Post-study immunotherapy confounds primary survival outcome (11/4/2019) ›Immunotherapy in elderly: diverse findings across the globe (11/4/2019) ›Comprehensive profiling in localised stage lung cancer (11/4/2019) ›Pembrolizumab may help some with advanced non-small-cell lung cancer (2/4/2019) ›Next-generation sequencing assay detects genetic variants driving cancer, resistance in NSCLC (2/4/2019) ›Cranial irradiation doesn't boost survival in locally advanced lung cancer (26/3/2019) ›Lung-cancer screens effective in asbestos-exposed smokers (14/3/2019) ›Liquid biopsy on par with tissue testing in advanced lung cancer (5/3/2019) ›Stereotactic ablative radiotherapy tops for inoperable early non-small-cell lung cancer (21/2/2019) ›It's never too late to quit smoking before lung surgery (16/1/2019) ›Lung cancer screening complications may be higher than expected (14/1/2019) ›Prognostic value of distant organ-specific metastases in newly diagnosed lung neuroendocrine tumours (26/9/2018) ›Unmet needs in surgical management of malignant pleural mesothelioma (26/9/2018) ›Spread through air spaces is prognostic in lung neuroendocrine tumours (26/9/2018) ›Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer (26/9/2018) ›New standard of care in extensive-stage small-cell lung cancer (26/9/2018) ›Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative (26/9/2018) ›Interview with IASCL President (26/9/2018) ›Combination therapies: Where are we in 2018? (26/9/2018) ›No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype (26/9/2018) ›Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer (26/9/2018) ›Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (26/9/2018) ›Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer (26/9/2018) ›Small-cell lung cancer circulating tumour cell derived explants (26/9/2018) ›Entrectinib treatment in patients with ROS1+ NSCLC (26/9/2018) ›Benefits of chest CT screening (26/9/2018) ›PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib (26/9/2018) ›Next generation immunotherapy in non-small-cell lung cancer (26/9/2018) ›Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer (26/9/2018) ›Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC (26/9/2018) ›Angiogenic and stromal biomarkers in malignant mesothelioma (26/9/2018) ›Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer (26/9/2018) ›

Subscribe for free ›

Stay up-to-date with Medicom. Subscribe to the Medicom Conference Reports and newsletter.

About us ›

Medicom provides the highest quality medical information and tools to international medical professionals.